Merck Expands BioReliance® Viral Clearance Offering in Singapore, Saving Customers Time

• Allows customers to continue developing lifesaving medicines amid Covid-19 pandemic
• Customers can view the lab studies “live” with Merck scientists

Singapore, September 15, 2020 — Merck, a leading science and technology company, today announced an expansion of its Singapore biosafety testing laboratory services. These services allow customers to conduct viral clearance studies that ensure the safety and quality of their biological drugs during the clinical development process.

“With Covid-19 travel restricted between many APAC countries, this expansion allows our customers to continue developing lifesaving medicines without having to travel to our BioReliance® laboratory in Singapore,” said Chris Ross, interim sector head of the Life Science business of Merck.

Viral capacity at Merck’s Singapore lab has increased by 50 percent to meet demand from biopharmaceutical and cell and gene therapy developers and manufacturers in Asia Pacific. Merck’s BioReliance® technical team performs viral capacity studies that adhere to the customer’s protocol using technology and process enhancements that allow the customer to have a similar experience remotely via secure, “live” feed video. Customers do not need to travel away from their home labs, and can watch experiments and receive real-time updates as their process runs. The complete viral clearance services offered by Merck scientists include inactivation, filtration and chromatography, all conducted in a Good Laboratory Practice environment. All services are supported by project managers fluent in Chinese, Japanese and Korean and help ensure the safe release of leading medicines to patients around the world.

“This expansion is especially timely, as it will facilitate faster and easier testing for biopharmaceutical companies in the region amid the ongoing Covid-19 pandemic,” said Ms. Goh Wan Yee, senior vice president, Healthcare, Singapore Economic Development Board. “In the long term, companies such as Merck contribute significantly to building a holistic supporting ecosystem which will enhance the biopharmaceutical industry.”

Singapore is a leading global science and technology research and development hub committed to growing the biomedical science sector, which has made the life science industry a key economic driver. Demand for viral clearance services has been increasing since the inauguration of Merck’s biosafety lab in Singapore in 2018. Travel restrictions related to the Covid-19 pandemic have accelerated the implementation of complete clearance services in the Singapore labs to support biologics customers in Asia. The complete viral clearance service is available in Singapore now, with the increased capacity coming online by April 2021.

Merck supports scientists around the world in efforts to accelerate development of treatments for and vaccines against Covid-19 by supplying materials, solutions and bioprocessing manufacturing platforms from its life science business. These offerings support more than 35 testing solutions, among them eight of the top 10 In-Vitro Diagnostic market leaders; more than 50 different vaccine candidates; and more than 20  monoclonal antibodies, plasma products and antivirals.

About Merck in Singapore

Merck established its presence in Singapore in 1973 to promote Merck products in South East Asia under E. Merck Pte. Ltd. (Singapore). Merck (Singapore) Pte Ltd. was founded on August 26, 1994. Merck Singapore is the regional headquarters in Asia Pacific with more than 360 employees supporting the healthcare, life science and performance materials businesses. Merck Singapore is also the regional training and application hub, offering technology transfer and services including testing, process optimization for the Life Science industry in the region.

The Life Science business sector of Merck offers a broad portfolio of tools and solutions with more than 300,000 products, ranging from lab water systems to gene editing tools, antibodies, cell lines, to end-to-end solutions to help customers in developing and manufacturing drugs. We work closely with our customers from academia, biotech and pharma to help deliver the promise of their work better, faster and safer.

The Healthcare business sector of Merck focuses on designing and developing medicines and intelligent devices that provide ongoing care for patients beyond their treatment. This includes new medications to treat conditions such as cancer or multiple sclerosis, but also innovative technologies that make life easier for patients. Our goal is to help people at every stage of life – also when it comes to creating new life especailly as the global market leader in fertility treatments. The Performance Materials business sector of Merck is a leading solutions provider in the premium segment of high-tech materials and functional specialty chemicals. These materials are widely used in the wafer fabs industry of Singapore.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.